Preclinical News and Research

RSS

Bionomics, Ironwood partner to develop and commercialize novel anti-anxiety compound

Ironwood Pharmaceuticals, Inc. and Bionomics Limited today announced that they entered into a collaboration, research, and licensing agreement that will enable Ironwood to develop and commercialize Bionomics' investigational anti-anxiety compound BNC210 and other related compounds.

5 Jan 2012

NGP receives investment from Abbott to develop NGP 555 for AD

NeuroGenetic Pharmaceuticals, Inc. (NGP), a privately held biopharmaceutical company focused on Alzheimer's disease (AD) therapeutics, has received an investment from Abbott Biotech Ventures.

5 Jan 2012

$Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer$

Viamet commences VT-464 Phase 1/2 trial in castration-refractory prostate cancer

Viamet Pharmaceuticals, Inc., announced today that dosing has begun in a Phase 1/2 clinical trial of VT-464, an oral, potent and lyase-selective CYP17 inhibitor for the treatment of castration-refractory prostate cancer.

4 Jan 2012

Task force identifies key themes and challenges in critical care research

To reduce mortality and improve patient care in the nation's ICUs, a task force formed by the Critical Care Societies Collaborative (CCSC), in conjunction with the US Critical Illness and Injury Trials Group (USCIITG) has recommended that research in the field become less fragmented and better account for patient heterogeneity and the complexity of critical illness.

4 Jan 2012

Antigen Express to move AE37 cancer vaccine into larger clinical trials

Generex Biotechnology Corporation today provided an update to the clinical development & regulatory strategy for its cancer vaccine, AE37.

4 Jan 2012

TrovaGene acquires license to mutations of SF3B1 splicing factor in CLL

TrovaGene, Inc., a developer of trans-renal molecular diagnostics, today announced that it has obtained an exclusive worldwide license to mutations of the SF3B1 splicing factor, which have been shown to be associated with disease progression and chemotherapy response in patients suffering from chronic lymphocytic leukemia.

3 Jan 2012

The Scientist selects Aspect Imaging's M2 imaging platform as one of Top 10 Innovations of 2011

The Scientist today unveiled the Top 10 Innovations of 2011 and selected Aspect Imaging's M2™ compact high-performance MRI imaging system as one the winners of this award. The Scientist invited members of the life science community to submit descriptions of exciting tools that made an impact in research this year and asked a panel of expert judges to evaluate the technologies.

2 Jan 2012

Speedy drug metabolism more likely to cause multidrug-resistant TB

A UT Southwestern Medical Center study using a sophisticated "glass mouse" research model has found that multidrug-resistant tuberculosis (TB) is more likely caused in patients by speedy drug metabolism rather than inconsistent doses, as is widely believed.

29 Dec 2011

Emergent commences Phase 2 combination trial of TRUw-016 with bendamustine in relapsed CLL

Emergent BioSolutions Inc. today announced the initiation of a Phase 2 study (protocol 16201) of TRU-016 in combination with bendamustine for patients with relapsed chronic lymphocytic leukemia (CLL).

29 Dec 2011

USPTO issues patent to Novus Scientific's TIGR Matrix Surgical Mesh

The Intellectual Property portfolio of TIGR Matrix Surgical Mesh has been further complimented with the granting of a second U.S. patent related to material degradation and mechanical behaviour.

27 Dec 2011

Allergan seeks to reassure surgeons, patients about safety of breast implants

Allergan, Inc. seeks to reassure patients and surgeons around the world utilizing Allergan's breast implant devices that its products are not part of the recent investigation into breast implant devices manufactured by French manufacturer, Poly Implant Prosthese (PIP) by regulatory authorities in Europe.

26 Dec 2011

Acceleron Pharma raises $30 million through private financing

Acceleron Pharma, Inc., a biopharmaceutical company developing protein therapeutics for cancer and orphan diseases, today announced it raised a $30M private financing.

23 Dec 2011

New way to awaken paternal Ube3a allele linked with Angelman syndrome

Results of a new study from the University of North Carolina at Chapel Hill may help pave the way to a treatment for a neurogenetic disorder often misdiagnosed as cerebral palsy or autism.

22 Dec 2011

MacroGenics to receive milestone payment from Boehringer Ingelheim

MacroGenics, Inc., a privately held biotechnology company that develops next generation antibody therapeutics, announced today that it will receive a milestone payment from Boehringer Ingelheim.

20 Dec 2011

MU Department of Surgery continues to secure research opportunities

The University of Maryland School of Medicine Department of Surgery is continuing to secure research opportunities to advance the science of medicine and improve patient outcomes, as evidenced by the grants awarded to the Department by the National Institutes of Health.

20 Dec 2011

EETs may also drive growth and spread of cancer

A group of small molecules called EETs - currently under scrutiny as possible treatment targets for a host of cardiovascular diseases - may also drive the growth and spread of cancer, according to researchers at the Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) and other institutions.

20 Dec 2011

New UA cancer research centre to focus on personalised treatment options

A new cancer research centre established at the University of Adelaide will focus on treatment options tailored to the individual, taking into account DNA and genetic variations between people.

20 Dec 2011

Blocking EETs may represent novel strategy for cancer therapy

Recent findings in mice suggest that blocking the production of small molecules produced in the body, known as epoxyeicosatrienoic acids (EETs), may represent a novel strategy for treating cancer by eliminating the blood vessels that feed cancer tumors.

20 Dec 2011

Individualised approach to cancer medicine considering genetic variations

A new cancer research centre established at the University of Adelaide will focus on treatment options tailored to the individual, taking into account DNA and genetic variations between people.

19 Dec 2011

EMA CHMP recommends approval for BioMarin's Novato manufacturing facility expansion

BioMarin Pharmaceutical Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval for the company's manufacturing facility expansion in Novato, CA.

19 Dec 2011